Evidence map›Paper›PMID 16127751›Full record

ArticleWorld journal of gastroenterology2005

Hepatocellular carcinoma in Egypt: a single center study over a decade.

Abdel-Rahman el-Zayadi, Hanaa M Badran, Eman M F Barakat, Mohy el-Deen Attia, Sherine Shawky, Mostafa K Mohamed, Osaima Selim, Ahmed Saeid

Abstract read
In one paragraph

Article in World journal of gastroenterology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 2 syntheses or guidelines pooled it, 152 citations in OpenAlex.

  1. Pooled it
  2. Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview.Journal of the Egyptian National Cancer Institute · 2020
    Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Role of miR-15b and miR-130b as Non-Invasive Biomarkers in Hepatocellular Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2025
    Article
  9. Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Pathogens and global health · 2022
    Observational
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Abdel-Rahman el-ZayadiDepartment of Tropical Medicine, Ain Shams University, Cairo, Egypt. clcz@tedata.net.eg
Hanaa M Badran
Eman M F Barakat
Mohy el-Deen Attia
Sherine Shawky
Mostafa K Mohamed
Osaima Selim
Ahmed Saeid
Ain Shams University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo identify the trend, possible risk factors and any pattern change of hepatocellular carcinoma (HCC) in Egypt over a decade.

methodsAll HCC patients attending Cairo Liver Center between January 1993 and December 2002, were enrolled in the study. Diagnosis of HCC was based on histopathological examination and/or detection of hepatic focal lesions by two imaging techniques plus alpha-fetoprotein level above 200 ng/mL. The duration of the study was divided into two periods of 5 years each; period I (1993-1997) and period II (1998-2002). Trend, demographic features of patients (age, gender, and residence), risk factors (HBsAg, HCV-Ab, schistosomiasis and others) and pattern of the focal lesions were compared between the two periods. Logistic regression model was fitted to calculate the adjusted odds ratios for the potential risk factors. The population attributable risk percentage was calculated to estimate the proportion of HCC attributed to hepatitis B and C viral infections.

resultsOver a decade, 1328 HCC patients out of 22,450 chronic liver disease (CLD) patients were diagnosed with an overall proportion of 5.9%. The annual proportion of HCC showed a significant rising trend from 4.0% in 1993 to 7.2% in 2002 (P = 0.000). A significant increase in male proportion from 82.5% to 87.6% (P = 0.009); M/F from 5:1 to 7:1 and a slight increase of the predominant age group (40-59 years) from 62.6% to 66.8% (P = 0.387) in periods I and II respectively, reflecting a shift to younger age group. In the bivariate analysis, HCC was significantly higher in rural residents, patients with history of schistosomiasis and/or blood transfusion. Yet, after adjustment, these variables did not have a significant risk for development of HCC. There was a significant decline of HBsAg from 38.6% to 20.5% (P = 0.000), and a slight increase of HCV-Ab from 85.6% to 87.9% in periods I and II respectively. HBV conferred a higher risk to develop HCC more than HCV in period I (OR 1.9 vs 1.6) and period II (OR 2.7 vs 2.0), but the relative contribution of HBV for development of HCC declined in period II compared to period I (PAR% 4.2%, 21.32%). At presentation, diagnostic alpha-fetoprotein level (> or = 200 ng/mL) was demonstrated in 15.6% vs 28.9% and small HCC (< or = 3 cm) represented 14.9% vs 22.7% (P = 0.0002) in periods I and II respectively.

conclusionOver a decade, there was nearly a twofold increase of the proportion of HCC among CLD patients in Egypt with a significant decline of HBV and slight increase of HCV as risk factors. Alpha-fetoprotein played a limited role in diagnosis of HCC, compared to imaging techniques. Increased detection of small lesions at presentation reflects increased awareness of the condition.

Indexed as

AdultAgedAge DistributionCarcinoma, HepatocellularEgyptFemaleHumansIncidenceLiver NeoplasmsMaleMiddle AgedRisk FactorsSex Distribution

Identifiers

PMID16127751
PMCPMC4320394
OpenAlexW2164942163

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.